Our experiments suggest that manipulation of this VEGF–ETS1–BRD4 transcriptional regulatory pathway may be a new avenue to ameliorate retinopathy, cancer, and other diseases of excessive angiogenesis. This evidence concerns the gene VEGFA and retinal disorder.